中国医院用药评价与分析2024，Vol.24Issue(9)：1123-1126,4.DOI:10.14009/j.issn.1672-2124.2024.09.022
尿毒清颗粒治疗慢性肾脏病的快速卫生技术评估
Rapid Health Technology Assessment on Niaoduqing Granules in the Treatment of Chronic Kidney Disease
摘要
Abstract
OBJECTIVE:To evaluate the efficacy,safety and economical efficiency of Niaoduqing granules in the treatment of chronic kidney disease(CKD)by rapid health technology assessment(HTA),so as to provide evidence-based evidence for clinic.METHODS:HTA reports,systematic reviews,Meta-analysis and pharmacoeconomics researches related to Niaoduqing granules for the treatment of CKD were enrolled by retrieving PubMed,the Cochrane Library,CBM,CNKI,Wanfang Data and VIP databases(search deadline until Feb.1st,2024),the quality of enrolled studies was evaluated and the results were qualitatively analyzed.RESULTS:A total of 13 Meta-analysis were enrolled,no HTA reports or pharmacoeconomics researches were retrieved.The results indicated that the clinical effective rate of the combined application of Niaoduqing granules for the treatment of CKD was better than other therapeutic regimens(the results of studies with the highest number of cases showed that RR=1.37,95%CI=1.24-1.51,P<0.001),and it could promote the endogenous creatinine clearance rate,glomerular filtration rate,hemoglobin level,which also had advantages in reducing serum creatinine,serum urea nitrogen,urinary albumin excretion rate,24 h urine protein,serum total cholesterol,serum triacylglycerol and cystatin C levels,with good safety and low incidence of adverse drug reactions.CONCLUSIONS:The combined application of Niaoduqing granules has good efficacy and safety in the treatment of CKD.It is necessary to further perform pharmacoeconomic research to supplement the economic evaluation evidence for the treatment of CKD.关键词
尿毒清颗粒/慢性肾脏病/有效性/安全性/经济性/快速卫生技术评估Key words
Niaoduqing granules/Chronic kidney disease/Effectiveness/Safety/Economical efficiency/Rapid health technology assessment分类
医药卫生引用本文复制引用
陈世祺,段银银,王洁,张晶晶,朱建国,顾冰,杭永付..尿毒清颗粒治疗慢性肾脏病的快速卫生技术评估[J].中国医院用药评价与分析,2024,24(9):1123-1126,4.基金项目
江苏省医学重点学科(No.ZDXK202247) （No.ZDXK202247）
苏州市科技发展计划指导性项目(No.SKYXD2022017) （No.SKYXD2022017）
